Results showed that both CD46 and CD55 were significantly downregulated by 2 to 7 folds in both AML and ALL patients compared to healthy controls which is suggestive of a defense mechanism conducted by leukemic cells to overcome immune defenses. Here, CD55 is linked to acute myeloid leukemia.